In vitro evaluation of an iodine radionuclide dosimeter (IRD) for continuous patient monitoring

In vivo dosimetry of the patients treated by I-131 is important from patient dosimetry and radiation protection points of view. Knowledge of delivered dose to the target volume and adjacent normal tissues can improve the effectiveness of radioiodine treatment. Herein, design, fabrication, and assessment processes of an iodine radionuclide dosimeter (IRD) are explained. Two CsI(Tl) scintillator crystals coupled to photodiodes were used in IRD fabrication with specifications derived from Monte Carlo (MC) simulation. Linearity, sensitivity, and long-term performance of the system were tested. Delivered dose due to a known administered activity of I-131 was calculated by MC simulation which was validated based on the Medical Internal Radiation Dose (MIRD) Committee formalism, and the calibration factor was provided. Using the current mode signal acquisition method, the system showed a linear response up to 8.2 GBq radioiodine activity to prohibit the pile-up error without a need for correction factor. On the other hand, IRD was sensitive down to the rarely detectable activity of 7.4 MBq. A prototype version of the IRD system has been developed to guide the hospital staff for the safe release of iodine – administered patients and to provide an insight for physicians about the delivered dose to the thyroid and nearby organs. Graphical abstract IRD attached to MIHAN.

[1]  L S Zuckier,et al.  Remotely pollable Geiger-Müller detector for continuous monitoring of iodine-131 therapy patients. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  Ernest Frimpong Asamoah,et al.  Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association. , 2011, Thyroid : official journal of the American Thyroid Association.

[3]  Alan E. Nahum,et al.  Handbook of Radiotherapy Physics: Theory and Practice , 2007 .

[4]  Jan B. A. Habraken,et al.  A method to measure the absorbed dose of the thyroid during I‐131 therapy, using a collar detector system and a SPECT acquisition , 2017, Medical physics.

[5]  G. Knoll Radiation detection and measurement , 1979 .

[6]  Thomas Krause,et al.  Technical Note: Determination of individual thyroid clearance effective half‐life with a common handheld electronic dosimeter , 2017, Medical physics.

[7]  J. Habraken,et al.  Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Markus Luster,et al.  EANM Dosimetry Committee Series on Standard Operational Procedures for Pre-Therapeutic Dosimetry II. Dosimetry prior to radioiodine therapy of benign thyroid diseases , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  Jai Hyuen Lee,et al.  Estimation of the Release Time from Isolation for Patients with Differentiated Thyroid Cancer Treated with High-dose I-131 , 2010, Nuclear medicine and molecular imaging.

[10]  Pat Perry,et al.  1. Introduction to health and safety , 2003 .

[11]  M Stasi,et al.  Red marrow and blood dosimetry in 131I treatment of metastatic thyroid carcinoma: pre-treatment versus in-therapy results , 2016, Physics in medicine and biology.

[12]  D Lizio,et al.  Absorbed fractions for photons in ellipsoidal volumes , 2009, Physics in medicine and biology.

[13]  Carlos D Venencia,et al.  Hospital discharge of patients with thyroid carcinoma treated with 131I. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  S. Tavernier Experimental Techniques in Nuclear and Particle Physics , 2010 .

[15]  Markus Luster,et al.  Dosimetry and thyroid cancer: the individual dosage of radioiodine. , 2010, Endocrine-related cancer.

[16]  S. K. Stephenson Introduction to Health Physics , 1969 .